Australian Government
Australian Participants in British Nuclear Tests (Treatment) Act 2006
Treatment Principles (Australian Participants in British Nuclear Tests) 2006 (Removal of Prior Approval Requirement for Optical Coherence Tomography) Instrument 2011
Instrument No. R21/2011
I, Warren Snowdon, Minister for Veterans’ Affairs, pursuant to subsection 16(7) of the Australian Participants in British Nuclear Tests (Treatment) Act 2006, approve this instrument made by the Repatriation Commission.
Dated this 23rd day of June 2011
Warren Snowdon
.................................................................................
WARREN SNOWDON
The Repatriation Commission, pursuant to subsection 16(6) of the Australian Participants in British Nuclear Tests (Treatment) Act 2006, varies the Treatment Principles (Australian Participants in British Nuclear Tests) 2006 (Instrument No.R30 of 2006), in accordance with the Schedule.
Dated this 20th day of May 2011
Ian Campbell…………Shane Carmody……Major General Mark Kelly AO DSC
IAN CAMPBELL SHANE CARMODY Major General Mark Kelly AO DSC
PRESIDENT DEPUTY PRESIDENT COMMISSIONER
[1] Name of Instrument
This instrument is the Treatment Principles (Australian Participants in British Nuclear Tests) 2006 (Removal of Prior Approval Requirement for Optical Coherence Tomography) Instrument 2011
[2] Commencement
This instrument is taken to have commenced on 1 May 2011.
Schedule
1. Paragraph 1.4.1 (definitions)
insert:
“Optical Coherence Tomography” means the treatment comprised of a non-contact, non-invasive high resolution
imaging technique that provides cross-sectional tomographic images of the ocular microstructure through the thickness of the retina.
2. Paragraph 3.2.1(b)
after:
Schedule
insert:
except where otherwise stated.
3. Paragraph 4.2.5
after paragraph 4.2.5, insert:
4.2.6 Optical Coherence Tomography
4.2.7 The Commission may accept financial responsibility for Optical Coherence Tomography (OCT) provided to an entitled person by an Ophthalmologist for the assessment or management of retinal disease.
Note: While OCT remains an unlisted treatment it is subject to all the requirements for an unlisted treatment except prior approval.